{"&cites=11484971735372092127&as_sdt=2005&sciodt=0,5&hl=en":[{"title":"Safety and activity of anti–PD-L1 antibody in patients with advanced cancer","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1200694","authors":["JR Brahmer","JR Brahmer SS Tykodi","JR Brahmer SS Tykodi LQM Chow…"],"year":2012,"numCitations":5915,"pdf":"https://www.nejm.org/doi/full/10.1056/NEJMoa1200694","citationUrl":"http://scholar.google.com/scholar?cites=13360512895833832804&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:ZH0zFbETarkJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=13360512895833832804&hl=en&as_sdt=2005&sciodt=0,5","publication":"Mass Medical Soc","p":1,"exp":1596881523436},{"title":"Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer","url":"https://www.nejm.org/doi/full/10.1056/nejmoa052306","authors":["MJ Piccart"],"year":2005,"numCitations":5369,"pdf":"https://www.nejm.org/doi/full/10.1056/nejmoa052306","citationUrl":"http://scholar.google.com/scholar?cites=1796034903430917809&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:se4zlzrM7BgJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=1796034903430917809&hl=en&as_sdt=2005&sciodt=0,5","publication":"Mass Medical Soc"},{"title":"Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1507643","authors":["H Borghaei","H Borghaei L Paz"],"year":2015,"numCitations":5368,"pdf":"https://www.nejm.org/doi/full/10.1056/NEJMoa1507643","citationUrl":"http://scholar.google.com/scholar?cites=15126636683086210345&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:KSW_Peub7NEJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=15126636683086210345&hl=en&as_sdt=2005&sciodt=0,5","publication":"Mass Medical Soc"},{"title":"Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer","url":"https://www.nejm.org/doi/full/10.1056/nejmoa1504627","authors":["J Brahmer","J Brahmer KL Reckamp","J Brahmer KL Reckamp P Baas","J Brahmer KL Reckamp P Baas L Crinò…"],"year":2015,"numCitations":5289,"pdf":"https://www.nejm.org/doi/full/10.1056/nejmoa1504627","citationUrl":"http://scholar.google.com/scholar?cites=18023613798475727448&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:WIL5qkG9IPoJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=18023613798475727448&hl=en&as_sdt=2005&sciodt=0,5","publication":"Mass Medical Soc"},{"title":"Pembrolizumab versus ipilimumab in advanced melanoma","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1503093","authors":["C Robert","C Robert J Schachter","C Robert J Schachter GV Long…"],"year":2015,"numCitations":3685,"pdf":"https://www.nejm.org/doi/full/10.1056/NEJMoa1503093","citationUrl":"http://scholar.google.com/scholar?cites=3000582073836731960&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:OH5xln81pCkJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=3000582073836731960&hl=en&as_sdt=2005&sciodt=0,5","publication":"Mass Medical Soc"},{"title":"Pembrolizumab for the treatment of non–small-cell lung cancer","url":"https://www.nejm.org/doi/full/10.1056/nejmoa1501824","authors":["EB Garon","EB Garon NA Rizvi","EB Garon NA Rizvi R Hui","EB Garon NA Rizvi R Hui N Leighl…"],"year":2015,"numCitations":3642,"pdf":"https://www.nejm.org/doi/full/10.1056/nejmoa1501824","citationUrl":"http://scholar.google.com/scholar?cites=4804110826968085903&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:j3UKB1ihq0IJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=4804110826968085903&hl=en&as_sdt=2005&sciodt=0,5","publication":"Mass Medical Soc"},{"title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","url":"https://www.sciencedirect.com/science/article/pii/S0140673615012817","authors":["RS Herbst","RS Herbst P Baas","RS Herbst P Baas DW Kim","RS Herbst P Baas DW Kim E Felip","RS Herbst P Baas DW Kim E Felip JL Pérez"],"year":2016,"numCitations":3459,"pdf":"https://www.researchgate.net/profile/Marcelo_Garrido/publication/287505140_Pembrolizumab_versus_docetaxel_for_previously_treated_PD-L1-positive_advanced_non-small-cell_lung_cancer_KEYNOTE-010_A_randomised_controlled_trial/links/5cddf42d299bf14d959f721f/Pembrolizumab-versus-docetaxel-for-previously-treated-PD-L1-positive-advanced-non-small-cell-lung-cancer-KEYNOTE-010-A-randomised-controlled-trial.pdf","citationUrl":"http://scholar.google.com/scholar?cites=10642977900179326521&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:OYaF5AJ0s5MJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=10642977900179326521&hl=en&as_sdt=2005&sciodt=0,5","publication":"Elsevier"},{"title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","url":"https://www.nature.com/articles/nature13954?page=4","authors":["PC Tumeh","PC Tumeh CL Harview","PC Tumeh CL Harview JH Yearley","PC Tumeh CL Harview JH Yearley IP Shintaku…"],"year":2014,"numCitations":3357,"pdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4246418/","citationUrl":"http://scholar.google.com/scholar?cites=8600773541923439091&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:88Hsr_cVXHcJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=8600773541923439091&hl=en&as_sdt=2005&sciodt=0,5","publication":"nature.com"},{"title":"Safety and tumor responses with lambrolizumab (anti–PD-1) in melanoma","url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1305133","authors":["O Hamid","O Hamid C Robert","O Hamid C Robert A Daud","O Hamid C Robert A Daud FS Hodi…"],"year":2013,"numCitations":3154,"pdf":"https://www.nejm.org/doi/full/10.1056/NEJMoa1305133","citationUrl":"http://scholar.google.com/scholar?cites=164069860268346458&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:WoykK6vkRgIJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=164069860268346458&hl=en&as_sdt=2005&sciodt=0,5","publication":"Mass Medical Soc"},{"title":"The future of immune checkpoint therapy","url":"https://science.sciencemag.org/content/348/6230/56.abstract","authors":["P Sharma","P Sharma JP Allison"],"year":2015,"numCitations":2228,"citationUrl":"http://scholar.google.com/scholar?cites=1385363128569161210&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:-uVJ62zMORMJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=1385363128569161210&hl=en&as_sdt=2005&sciodt=0,5","publication":"science.sciencemag.org"}]}